Fig. 1: LSC17 in TCGA AML based on age.

a–d Kaplan–Meier estimates for the probability of event free survival (EFS) and overall survival (OS) in patients from The Cancer Genome Atlas (TCGA) AML cohort segregated based on age. a, b LSC17 scores predict survival in younger adults (<60 years of age). c, d Conversely, LSC17 scores do not discriminate between favorable and unfavorable outcomes in older adults (≥60 years of age). Survival differences were determined using the log-rank test (two-sided and without multiple-testing adjustments). e Schematic diagram for our experimental design. Our data set consists of primary samples that were obtained at the time of diagnosis after enrollment in one of four clinical trials listed in the left panel (black). Specific data analyses and associated figures are noted in the bottom panel (gray). Samples underwent either polyadenylation enrichment or ribosomal RNA depletion. Stratified randomization was performed based on fusion category to generate two cohorts for risk model training and validation.